STEAP1 and Ewing sarcoma: Grunewald et al. also found that STEAP1 can serve as an immunohistological marker for patients with ES; 71 of 114 (62.3%) ES samples displayed detectable membranous STEAP1 immunoreactivity, making STEAP1 a potential therapeutic target (159).